These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. New developments in the staging of melanoma. Baruch AC; Shi J; Feng Y; Nelson MA Cancer Invest; 2005; 23(6):561-7. PubMed ID: 16203664 [TBL] [Abstract][Full Text] [Related]
9. The classification of cutaneous melanoma. Duncan LM Hematol Oncol Clin North Am; 2009 Jun; 23(3):501-13, ix. PubMed ID: 19464599 [TBL] [Abstract][Full Text] [Related]
10. [Clinical and biological heterogeneity of melanomas]. Delyon J; Mourah S; Lebbé C Rev Prat; 2014 Jan; 64(1):72-3. PubMed ID: 24649551 [No Abstract] [Full Text] [Related]
11. Challenging the heterogeneity of disease presentation in malignant melanoma-impact on patient treatment. Marcell Szasz A; Malm J; Rezeli M; Sugihara Y; Betancourt LH; Rivas D; Gyorffy B; Marko-Varga G Cell Biol Toxicol; 2019 Feb; 35(1):1-14. PubMed ID: 30357519 [TBL] [Abstract][Full Text] [Related]
12. Cutaneous malignant melanoma: update on diagnostic and prognostic biomarkers. Abbas O; Miller DD; Bhawan J Am J Dermatopathol; 2014 May; 36(5):363-79. PubMed ID: 24803061 [TBL] [Abstract][Full Text] [Related]
13. Tumor necrosis factor receptor superfamily member TROY is a novel melanoma biomarker and potential therapeutic target. Spanjaard RA; Whren KM; Graves C; Bhawan J Int J Cancer; 2007 Mar; 120(6):1304-10. PubMed ID: 17187358 [TBL] [Abstract][Full Text] [Related]
14. Classification and staging of melanoma. Gershenwald JE; Buzaid AC; Ross MI Clin Lab Med; 2000 Dec; 20(4):785-815. PubMed ID: 11221515 [TBL] [Abstract][Full Text] [Related]
15. The EORTC melanoma group translational research program on prognostic factors and ultrastaging in association with the adjuvant therapy trials in stage II and stage III melanoma. European Organization for Research and Treatment of Cancer. Eggermont AM; Keilholz U; Testori A; Cook M; Lienard D; Ruiter DJ Ann Surg Oncol; 2001 Oct; 8(9 Suppl):38S-40S. PubMed ID: 11599896 [TBL] [Abstract][Full Text] [Related]
16. Update on primary mucosal melanoma. Tacastacas JD; Bray J; Cohen YK; Arbesman J; Kim J; Koon HB; Honda K; Cooper KD; Gerstenblith MR J Am Acad Dermatol; 2014 Aug; 71(2):366-75. PubMed ID: 24815565 [TBL] [Abstract][Full Text] [Related]
17. Treatment implications of the emerging molecular classification system for melanoma. Romano E; Schwartz GK; Chapman PB; Wolchock JD; Carvajal RD Lancet Oncol; 2011 Sep; 12(9):913-22. PubMed ID: 21349766 [TBL] [Abstract][Full Text] [Related]
18. Assessing Response to New Treatments and Prognosis in Melanoma Patients, by the Biomarker S-100β. Barak V; Leibovici V; Peretz T; Kalichman I; Lotem M; Merims S Anticancer Res; 2015 Dec; 35(12):6755-60. PubMed ID: 26637892 [TBL] [Abstract][Full Text] [Related]
19. Chromatin barcodes as biomarkers for melanoma. Bastonini E; Jeznach M; Field M; Juszczyk K; Corfield E; Dezfouli M; Ahmat N; Smith A; Womersley H; Jordan P; Ramadass A; Akoulitchev A; Goding CR Pigment Cell Melanoma Res; 2014 Sep; 27(5):788-800. PubMed ID: 24807349 [TBL] [Abstract][Full Text] [Related]
20. Tumor-infiltrating lymphocyte therapy for melanoma: rationale and issues for further clinical development. Sim GC; Chacon J; Haymaker C; Ritthipichai K; Singh M; Hwu P; Radvanyi L BioDrugs; 2014 Oct; 28(5):421-37. PubMed ID: 24890028 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]